Detalhe da pesquisa
1.
Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice.
Haematologica
; 108(8): 2192-2204, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36546453
2.
High dimensional surrogacy: computational aspects of an upscaled analysis.
J Biopharm Stat
; 30(1): 104-120, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-31462134
3.
Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma.
Adv Ther
; 41(4): 1576-1593, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38402374
4.
Indirect adjusted comparison of 6-month clinical outcomes between esketamine nasal spray and other real-world polypharmacy treatment strategies for treatment resistant depression: results from the ICEBERG study.
Front Psychiatry
; 14: 1250987, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38025416
5.
ICEBERG study: an indirect adjusted comparison estimating the long-term benefit of esketamine nasal spray when compared with routine treatment of treatment resistant depression in general psychiatry.
Front Psychiatry
; 14: 1250980, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38025433
6.
An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations.
Adv Ther
; 40(3): 1187-1203, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36652175
7.
Adjusted Comparison of Outcomes between Patients from CARTITUDE-1 versus Multiple Myeloma Patients with Prior Exposure to PI, Imid and Anti-CD-38 from a German Registry.
Cancers (Basel)
; 13(23)2021 Nov 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-34885106
8.
Adjusting Overall Survival Estimates for Treatment Switching in Metastatic, Castration-Sensitive Prostate Cancer: Results from the LATITUDE Study.
Target Oncol
; 14(6): 681-688, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31754962